{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T17:37:37Z","timestamp":1781804257222,"version":"3.54.5"},"reference-count":146,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2026,4,27]],"date-time":"2026-04-27T00:00:00Z","timestamp":1777248000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,4,27]],"date-time":"2026-04-27T00:00:00Z","timestamp":1777248000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Neurol"],"published-print":{"date-parts":[[2026,5]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Multiple sclerosis (MS), neuromyelitis optica spectrum disorder (NMOSD), and myelin oligodendrocyte glycoprotein-associated disease (MOGAD) are the major types of demyelinating disorders of the central nervous system (CNS). Demyelinating disorders impact women disproportionately and frequently present during reproductive years. These conditions can cause significant neurological disability and psychosocial challenges, especially for women. Because they often present during reproductive years, clinicians frequently manage contraception, pregnancy, and the postpartum period alongside disease control. Sex-specific evidence, therefore, becomes especially important for treatment decisions. Despite this, sex-specific differences in epidemiology, immunopathology, clinical features, and therapeutic response remain inconsistently addressed in both clinical practice and research. In this review, we synthesize current evidence on the factors underlying the female predominance observed in MS, NMOSD, and MOGAD, and discuss the clinical consequences of these findings. We investigate the influence of sex hormones, X-chromosome\u2013mediated immune regulation, and immunological changes associated with pregnancy and the postpartum period, as well as disease-specific mechanisms. We also examine how these factors affect diagnosis, prognosis, therapeutic decision-making, pregnancy management, and quality of life. Finally, we highlight important gaps in knowledge and underscore the necessity for a sex-informed approach to the diagnosis, management, and research of autoimmune demyelinating diseases.<\/jats:p>","DOI":"10.1007\/s00415-026-13831-z","type":"journal-article","created":{"date-parts":[[2026,4,27]],"date-time":"2026-04-27T10:44:30Z","timestamp":1777286670000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Demyelinating disorders in women: epidemiology, immunology, and clinical implications across MS, NMOSD, and MOGAD"],"prefix":"10.1007","volume":"273","author":[{"ORCID":"https:\/\/orcid.org\/0009-0003-2360-0025","authenticated-orcid":false,"given":"Gabriel","family":"Ind","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zain","family":"Hashmi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shivansh","family":"Ahuja","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tamara","family":"Fayad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zaneh","family":"Kahook","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rumaiza","family":"Ahmad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Syeda Maryam","family":"Batool","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keziah Mariam","family":"Jiji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hafsah","family":"Hudli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shamera","family":"Hossain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ali","family":"Lafi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdallah","family":"AbuJlambo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,27]]},"reference":[{"key":"13831_CR1","doi-asserted-by":"publisher","DOI":"10.1007\/978-3-031-50675-8_13","author":"F Barkhof","year":"2024","unstructured":"Barkhof F, Koeller KK (2024) Demyelinating diseases of the CNS diseases of the brain, head and neck, spine 2024\u20132027. Diagn Imaging. https:\/\/doi.org\/10.1007\/978-3-031-50675-8_13","journal-title":"Diagn Imaging"},{"issue":"9648","key":"13831_CR2","doi-asserted-by":"publisher","first-page":"1502","DOI":"10.1016\/S0140-6736(08)61620-7","volume":"372","author":"A Compston","year":"2008","unstructured":"Compston A, Coles A (2008) Multiple sclerosis. Lancet 372(9648):1502\u20131517. https:\/\/doi.org\/10.1016\/S0140-6736(08)61620-7","journal-title":"Lancet"},{"issue":"2","key":"13831_CR3","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1038\/s41582-018-0112-x","volume":"15","author":"M Reindl","year":"2019","unstructured":"Reindl M, Waters P (2019) Myelin oligodendrocyte glycoprotein antibodies in neurological disease. Nat Rev Neurol 15(2):89\u2013102. https:\/\/doi.org\/10.1038\/s41582-018-0112-x","journal-title":"Nat Rev Neurol"},{"issue":"2","key":"13831_CR4","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1212\/WNL.0000000000001729","volume":"85","author":"DM Wingerchuk","year":"2015","unstructured":"Wingerchuk DM, Banwell B, Bennett JL, Cabre P, Carroll W, Chitnis T et al (2015) International consensus diagnostic criteria for neuromyelitis optica spectrum disorders. Neurology 85(2):177\u2013189. https:\/\/doi.org\/10.1212\/WNL.0000000000001729","journal-title":"Neurology"},{"issue":"4","key":"13831_CR5","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1016\/S1474-4422(24)00038-3","volume":"23","author":"JD Steinmetz","year":"2024","unstructured":"Steinmetz JD, Seeher KM, Schiess N, Nichols E, Cao B, Servili C et al (2024) Global, regional, and national burden of disorders affecting the nervous system, 1990\u20132021: a systematic analysis for the Global Burden of Disease Study 2021. Lancet Neurol 23(4):344\u2013381. https:\/\/doi.org\/10.1016\/S1474-4422(24)00038-3","journal-title":"Lancet Neurol"},{"key":"13831_CR6","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1016\/B978-0-12-802395-2.00019-5","volume":"145","author":"R H\u00f6ftberger","year":"2017","unstructured":"H\u00f6ftberger R, Lassmann H (2017) Inflammatory demyelinating diseases of the central nervous system. Handb Clin Neurol 145:263\u2013283. https:\/\/doi.org\/10.1016\/B978-0-12-802395-2.00019-5","journal-title":"Handb Clin Neurol"},{"issue":"2","key":"13831_CR7","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1212\/WNL.0000000000011153","volume":"96","author":"V Papp","year":"2021","unstructured":"Papp V, Magyari M, Aktas O, Berger T, Broadley SA, Cabre P et al (2021) Worldwide incidence and prevalence of neuromyelitis optica: a systematic review. Neurology 96(2):59\u201377. https:\/\/doi.org\/10.1212\/WNL.0000000000011153","journal-title":"Neurology"},{"issue":"6","key":"13831_CR8","doi-asserted-by":"publisher","first-page":"1905","DOI":"10.1007\/s10072-023-06617-y","volume":"44","author":"S Bagherieh","year":"2023","unstructured":"Bagherieh S, Afshari-Safavi A, Vaheb S, Kiani M, Ghaffary EM, Barzegar M et al (2023) Worldwide prevalence of neuromyelitis optica spectrum disorder (NMOSD) and neuromyelitis optica (NMO): a systematic review and meta-analysis. Neurol Sci 44(6):1905\u20131915. https:\/\/doi.org\/10.1007\/s10072-023-06617-y","journal-title":"Neurol Sci"},{"key":"13831_CR9","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1016\/bs.irn.2022.06.011","volume":"164","author":"L Diem","year":"2022","unstructured":"Diem L, Hammer H, Hoepner R, Pistor M, Remlinger J, Salmen A (2022) Sex and gender differences in autoimmune demyelinating CNS disorders: multiple sclerosis (MS), neuromyelitis optica spectrum disorder (NMOSD) and myelin-oligodendrocyte-glycoprotein antibody associated disorder (MOGAD). Int Rev Neurobiol 164:129\u2013178","journal-title":"Int Rev Neurobiol"},{"key":"13831_CR10","doi-asserted-by":"publisher","DOI":"10.1016\/j.lanwpc.2020.100021","volume":"2","author":"D-C Tian","year":"2020","unstructured":"Tian D-C, Li Z, Yuan M, Zhang C, Gu H, Wang Y et al (2020) Incidence of neuromyelitis optica spectrum disorder (NMOSD) in China: a national population-based study. Lancet Reg Health West Pac 2:100021. https:\/\/doi.org\/10.1016\/j.lanwpc.2020.100021","journal-title":"Lancet Reg Health West Pac"},{"issue":"11","key":"13831_CR11","doi-asserted-by":"publisher","first-page":"932","DOI":"10.1016\/S1474-4422(06)70581-6","volume":"5","author":"S-M Orton","year":"2006","unstructured":"Orton S-M, Herrera BM, Yee IM, Valdar W, Ramagopalan SV, Sadovnick AD et al (2006) Sex ratio of multiple sclerosis in Canada: a longitudinal study. Lancet Neurol 5(11):932\u2013936. https:\/\/doi.org\/10.1016\/S1474-4422(06)70581-6","journal-title":"Lancet Neurol"},{"issue":"10","key":"13831_CR12","doi-asserted-by":"publisher","first-page":"626","DOI":"10.1038\/nri.2016.90","volume":"16","author":"SL Klein","year":"2016","unstructured":"Klein SL, Flanagan KL (2016) Sex differences in immune responses. Nat Rev Immunol 16(10):626\u2013638. https:\/\/doi.org\/10.1038\/nri.2016.90","journal-title":"Nat Rev Immunol"},{"issue":"3","key":"13831_CR13","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1016\/j.yfrne.2014.04.004","volume":"35","author":"ST Ngo","year":"2014","unstructured":"Ngo ST, Steyn FJ, McCombe PA (2014) Gender differences in autoimmune disease. Front Neuroendocrinol 35(3):347\u2013369. https:\/\/doi.org\/10.1016\/j.yfrne.2014.04.004","journal-title":"Front Neuroendocrinol"},{"issue":"5","key":"13831_CR14","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1210\/er.2007-0001","volume":"28","author":"RH Straub","year":"2007","unstructured":"Straub RH (2007) The complex role of estrogens in inflammation. Endocr Rev 28(5):521\u2013574. https:\/\/doi.org\/10.1210\/er.2007-0001","journal-title":"Endocr Rev"},{"issue":"8","key":"13831_CR15","doi-asserted-by":"publisher","first-page":"594","DOI":"10.1038\/nri2815","volume":"10","author":"C Libert","year":"2010","unstructured":"Libert C, Dejager L, Pinheiro I (2010) The X chromosome in immune functions: when a chromosome makes the difference. Nat Rev Immunol 10(8):594\u2013604. https:\/\/doi.org\/10.1038\/nri2815","journal-title":"Nat Rev Immunol"},{"issue":"19","key":"13831_CR16","doi-asserted-by":"publisher","DOI":"10.1126\/sciimmunol.aap8855","volume":"3","author":"M Souyris","year":"2018","unstructured":"Souyris M, Cenac C, Azar P, Daviaud D, Canivet A, Grunenwald S et al (2018) TLR7 escapes X chromosome inactivation in immune cells. Sci Immunol 3(19):eaap8855. https:\/\/doi.org\/10.1126\/sciimmunol.aap8855","journal-title":"Sci Immunol"},{"issue":"7","key":"13831_CR17","doi-asserted-by":"publisher","first-page":"E1520","DOI":"10.1073\/pnas.1710401115","volume":"115","author":"AE Russi","year":"2018","unstructured":"Russi AE, Ebel ME, Yang Y, Brown MA (2018) Male-specific IL-33 expression regulates sex-dimorphic EAE susceptibility. Proc Natl Acad Sci U S A 115(7):E1520\u2013E1529. https:\/\/doi.org\/10.1073\/pnas.1710401115","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"6","key":"13831_CR18","doi-asserted-by":"publisher","first-page":"1353","DOI":"10.1093\/brain\/awh152","volume":"127","author":"S Vukusic","year":"2004","unstructured":"Vukusic S, Hutchinson M, Hours M, Moreau T, Cortinovis-Tourniaire P, Adeleine P et al (2004) Pregnancy and multiple sclerosis (the PRIMS study): clinical predictors of post-partum relapse. Brain 127(6):1353\u20131360. https:\/\/doi.org\/10.1093\/brain\/awh152","journal-title":"Brain"},{"issue":"5","key":"13831_CR19","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1056\/NEJM199807303390501","volume":"339","author":"C Confavreux","year":"1998","unstructured":"Confavreux C, Hutchinson M, Hours MM, Cortinovis-Tourniaire P, Moreau T, Group PiMS (1998) Rate of pregnancy-related relapse in multiple sclerosis. N Engl J Med 339(5):285\u2013291. https:\/\/doi.org\/10.1056\/NEJM199807303390501","journal-title":"N Engl J Med"},{"key":"13831_CR20","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2020.102241","volume":"44","author":"R Dobson","year":"2020","unstructured":"Dobson R, Jokubaitis VG, Giovannoni G (2020) Change in pregnancy-associated multiple sclerosis relapse rates over time: a meta-analysis. Mult Scler Relat Disord 44:102241. https:\/\/doi.org\/10.1016\/j.msard.2020.102241","journal-title":"Mult Scler Relat Disord"},{"issue":"3","key":"13831_CR21","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1007\/s13167-018-0143-9","volume":"9","author":"N Borisow","year":"2018","unstructured":"Borisow N, Hellwig K, Paul F (2018) Neuromyelitis optica spectrum disorders and pregnancy: relapse-preventive measures and personalized treatment strategies. EPMA J 9(3):249\u2013256. https:\/\/doi.org\/10.1007\/s13167-018-0143-9","journal-title":"EPMA J"},{"key":"13831_CR22","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2021.697974","volume":"12","author":"IL Simone","year":"2021","unstructured":"Simone IL, Tortorella C, Ghirelli A (2021) Influence of pregnancy in multiple sclerosis and impact of disease-modifying therapies. Front Neurol 12:697974. https:\/\/doi.org\/10.3389\/fneur.2021.697974","journal-title":"Front Neurol"},{"issue":"7","key":"13831_CR23","doi-asserted-by":"publisher","first-page":"716","DOI":"10.1136\/jnnp-2022-328994","volume":"93","author":"M Magyari","year":"2022","unstructured":"Magyari M, Koch-Henriksen N (2022) Quantitative effect of sex on disease activity and disability accumulation in multiple sclerosis. J Neurol Neurosurg Psychiatry 93(7):716\u2013722. https:\/\/doi.org\/10.1136\/jnnp-2022-328994","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"6","key":"13831_CR24","doi-asserted-by":"publisher","first-page":"3256","DOI":"10.1007\/s00415-024-12270-y","volume":"271","author":"H Hegen","year":"2024","unstructured":"Hegen H, Berek K, Deisenhammer F, Berger T, Enzinger C, Guger M et al (2024) Sex impacts treatment decisions in multiple sclerosis. J Neurol 271(6):3256\u20133267. https:\/\/doi.org\/10.1007\/s00415-024-12270-y","journal-title":"J Neurol"},{"issue":"9","key":"13831_CR25","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1016\/j.nrleng.2021.01.008","volume":"38","author":"M Alonso-Moreno","year":"2023","unstructured":"Alonso-Moreno M, Ladr\u00f3n-Guevara M, Ciudad-Guti\u00e9rrez P (2023) Systematic review of gender bias in clinical trials of monoclonal antibodies for the treatment of multiple sclerosis. Neurolog\u00eda (English Edition) 38(9):695\u2013706. https:\/\/doi.org\/10.1016\/j.nrleng.2021.01.008","journal-title":"Neurolog\u00eda (English Edition)"},{"issue":"14","key":"13831_CR26","doi-asserted-by":"publisher","first-page":"1816","DOI":"10.1177\/1352458520970841","volume":"26","author":"C Walton","year":"2020","unstructured":"Walton C, King R, Rechtman L, Kaye W, Leray E, Marrie RA et al (2020) Rising prevalence of multiple sclerosis worldwide: insights from the Atlas of MS. Mult Scler 26(14):1816\u20131821. https:\/\/doi.org\/10.1177\/1352458520970841","journal-title":"Mult Scler"},{"key":"13831_CR27","unstructured":"Multiple Sclerosis International Federation. Atlas of MS: female-to-male ratio of people with multiple sclerosis. 2025. Available from: https:\/\/atlasofms.org\/"},{"key":"13831_CR28","unstructured":"Multiple Sclerosis International Federation. Number of people with multiple sclerosis. 2023. Available from: https:\/\/atlasofms.org\/"},{"issue":"4","key":"13831_CR29","doi-asserted-by":"publisher","first-page":"375","DOI":"10.5603\/PJNNS.103955","volume":"59","author":"K Kapica-Topczewska","year":"2025","unstructured":"Kapica-Topczewska K, Ku\u0142akowska A, Kochanowicz J, Brola W (2025) Epidemiology of multiple sclerosis: global trends, regional differences, and clinical implications. Neurol Neurochir Pol 59(4):375\u2013384. https:\/\/doi.org\/10.5603\/PJNNS.103955","journal-title":"Neurol Neurochir Pol"},{"issue":"1","key":"13831_CR30","doi-asserted-by":"publisher","DOI":"10.1177\/20552173251326173","volume":"11","author":"A Maunula","year":"2025","unstructured":"Maunula A, Laakso SM, Viitala M, Soilu-H\u00e4nninen M, Sumelahti M-L, Atula S (2025) Incidence and prevalence of multiple sclerosis during eras of evolving diagnostic criteria\u2014a nationwide population-based registry study over five decades. Mult Scler J Exp Transl Clin 11(1):20552173251326173. https:\/\/doi.org\/10.1177\/20552173251326173","journal-title":"Mult Scler J Exp Transl Clin"},{"issue":"10","key":"13831_CR31","doi-asserted-by":"publisher","first-page":"1485","DOI":"10.1212\/01.WNL.0000216139.44259.74","volume":"66","author":"DM Wingerchuk","year":"2006","unstructured":"Wingerchuk DM, Lennon V, Pittock S, Lucchinetti C, Weinshenker B (2006) Revised diagnostic criteria for neuromyelitis optica. Neurology 66(10):1485\u20131489. https:\/\/doi.org\/10.1212\/01.WNL.0000216139.44259.74","journal-title":"Neurology"},{"key":"13831_CR32","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2023.1260358","volume":"14","author":"JY Hor","year":"2023","unstructured":"Hor JY, Fujihara K (2023) Epidemiology of myelin oligodendrocyte glycoprotein antibody-associated disease: a review of prevalence and incidence worldwide. Front Neurol 14:1260358. https:\/\/doi.org\/10.3389\/fneur.2023.1260358","journal-title":"Front Neurol"},{"key":"13831_CR33","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2020.00616","volume":"11","author":"F Gilli","year":"2020","unstructured":"Gilli F, DiSano KD, Pachner AR (2020) SeXX matters in multiple sclerosis. Front Neurol 11:616. https:\/\/doi.org\/10.3389\/fneur.2020.00616","journal-title":"Front Neurol"},{"issue":"8","key":"13831_CR34","doi-asserted-by":"publisher","first-page":"4794","DOI":"10.1007\/s00415-024-12452-8","volume":"271","author":"S Arnett","year":"2024","unstructured":"Arnett S, Chew SH, Leitner U, Hor JY, Paul F, Yeaman MR et al (2024) Sex ratio and age of onset in AQP4 antibody-associated NMOSD: a review and meta-analysis. J Neurol 271(8):4794\u20134812. https:\/\/doi.org\/10.1007\/s00415-024-12452-8","journal-title":"J Neurol"},{"key":"13831_CR35","unstructured":"Multiple Sclerosis International Federation. Atlas of MS FAQs. 2025. Available from: https:\/\/atlasofms.org\/faqs"},{"issue":"4","key":"13831_CR36","doi-asserted-by":"publisher","first-page":"1610","DOI":"10.1007\/s00415-023-12047-9","volume":"271","author":"A Habbestad","year":"2024","unstructured":"Habbestad A, Willumsen JS, Aarseth JH, Grytten N, Midgard R, Wergeland S et al (2024) Increasing age of multiple sclerosis onset from 1920 to 2022: a population-based study. J Neurol 271(4):1610\u20131617. https:\/\/doi.org\/10.1007\/s00415-023-12047-9","journal-title":"J Neurol"},{"issue":"10","key":"13831_CR37","doi-asserted-by":"publisher","first-page":"1137","DOI":"10.1136\/jnnp-2022-329049","volume":"93","author":"L Prosperini","year":"2022","unstructured":"Prosperini L, Lucchini M, Ruggieri S, Tortorella C, Haggiag S, Mirabella M et al (2022) Shift of multiple sclerosis onset towards older age. J Neurol Neurosurg Psychiatry 93(10):1137\u20131139. https:\/\/doi.org\/10.1136\/jnnp-2022-329049","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"22","key":"13831_CR38","doi-asserted-by":"publisher","first-page":"e2089","DOI":"10.1212\/WNL.0000000000006574","volume":"91","author":"S-H Kim","year":"2018","unstructured":"Kim S-H, Mealy MA, Levy M, Schmidt F, Ruprecht K, Paul F et al (2018) Racial differences in neuromyelitis optica spectrum disorder. Neurology 91(22):e2089\u2013e2099. https:\/\/doi.org\/10.1212\/WNL.0000000000006574","journal-title":"Neurology"},{"key":"13831_CR39","doi-asserted-by":"publisher","first-page":"501","DOI":"10.3389\/fneur.2020.00501","volume":"11","author":"JY Hor","year":"2020","unstructured":"Hor JY, Asgari N, Nakashima I, Broadley SA, Leite MI, Kissani N et al (2020) Epidemiology of neuromyelitis optica spectrum disorder and its prevalence and incidence worldwide. Front Neurol 11:501. https:\/\/doi.org\/10.3389\/fneur.2020.00501","journal-title":"Front Neurol"},{"key":"13831_CR40","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2022.103884","volume":"63","author":"R Orlandi","year":"2022","unstructured":"Orlandi R, Mariotto S, Gajofatto A (2022) Prevalence, incidence, and season distribution of MOG antibody-associated disease in the province of Verona. Italy Mult Scler Relat Disord 63:103884. https:\/\/doi.org\/10.1016\/j.msard.2022.103884","journal-title":"Italy Mult Scler Relat Disord"},{"issue":"1","key":"13831_CR41","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1186\/s12916-025-03875-9","volume":"23","author":"M-T Cai","year":"2025","unstructured":"Cai M-T, Hua Y, Lai Q-L, Su S-Y, Shen C-H, Qiao S et al (2025) Performance of the 2023 diagnostic criteria for MOGAD: real-world application in a Chinese multicenter cohort of pediatric and adult patients. BMC Med 23(1):40. https:\/\/doi.org\/10.1186\/s12916-025-03875-9","journal-title":"BMC Med"},{"issue":"1","key":"13831_CR42","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.neurol.2015.10.006","volume":"172","author":"E Leray","year":"2016","unstructured":"Leray E, Moreau T, Fromont A, Edan G (2016) Epidemiology of multiple sclerosis. Rev Neurol (Paris) 172(1):3\u201313. https:\/\/doi.org\/10.1016\/j.neurol.2015.10.006","journal-title":"Rev Neurol (Paris)"},{"issue":"1","key":"13831_CR43","doi-asserted-by":"publisher","first-page":"2","DOI":"10.3390\/neurolint18010002","volume":"18","author":"VM Rivera","year":"2025","unstructured":"Rivera VM (2025) Multiple sclerosis: an ethnically diverse disease with worldwide equity challenges accessing care. Neurol Int 18(1):2. https:\/\/doi.org\/10.3390\/neurolint18010002","journal-title":"Neurol Int"},{"issue":"5","key":"13831_CR44","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1016\/j.orcp.2024.11.005","volume":"18","author":"M Mohammadi","year":"2024","unstructured":"Mohammadi M, Mohammadi A, Habibzadeh A, Korkorian R, Mohamadi M, Shaygannejad V et al (2024) Abnormal body mass index is associated with risk of multiple sclerosis: a systematic review and meta-analysis. Obes Res Clin Pract 18(5):311\u2013321. https:\/\/doi.org\/10.1016\/j.orcp.2024.11.005","journal-title":"Obes Res Clin Pract"},{"issue":"2","key":"13831_CR45","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1007\/s100720170011","volume":"22","author":"G Rosati","year":"2001","unstructured":"Rosati G (2001) The prevalence of multiple sclerosis in the world: an update. Neurol Sci 22(2):117\u2013139. https:\/\/doi.org\/10.1007\/s100720170011","journal-title":"Neurol Sci"},{"issue":"7 Pt 2","key":"13831_CR46","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1212\/WNL.30.7_Part_2.61","volume":"30","author":"JF Kurtzke","year":"1980","unstructured":"Kurtzke JF (1980) Epidemiologic contributions to multiple sclerosis: an overview. Neurology 30(7 Pt 2):61\u201379. https:\/\/doi.org\/10.1212\/WNL.30.7_Part_2.61","journal-title":"Neurology"},{"issue":"6","key":"13831_CR47","doi-asserted-by":"publisher","first-page":"642","DOI":"10.1177\/13524585251328554","volume":"31","author":"A Lee","year":"2025","unstructured":"Lee A, Iordanova RT, Smith JB, Li BH, Schwarzmann KB, Alsalek S et al (2025) Incidence and prevalence of neuromyelitis optica spectrum disorder in a contemporary, multi-ethnic cohort. Mult Scler J 31(6):642\u2013657. https:\/\/doi.org\/10.1177\/13524585251328554","journal-title":"Mult Scler J"},{"issue":"4","key":"13831_CR48","doi-asserted-by":"publisher","first-page":"1817","DOI":"10.1007\/s00415-021-10782-5","volume":"269","author":"M Puthenparampil","year":"2022","unstructured":"Puthenparampil M, Perini P, Bergamaschi R, Capobianco M, Filippi M, Gallo P (2022) Multiple sclerosis epidemiological trends in Italy highlight the environmental risk factors. J Neurol 269(4):1817\u20131824. https:\/\/doi.org\/10.1007\/s00415-021-10782-5","journal-title":"J Neurol"},{"issue":"1","key":"13831_CR49","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-020-80535-3","volume":"11","author":"MP Alvarenga","year":"2021","unstructured":"Alvarenga MP, do Carmo LF, Vasconcelos CCF, Alvarenga MP, Alvarenga-Filho H, de Melo Bento CA et al (2021) Neuromyelitis optica is an HLA associated disease different from multiple sclerosis: a systematic review with meta-analysis. Sci Rep 11(1):152. https:\/\/doi.org\/10.1038\/s41598-020-80535-3","journal-title":"Sci Rep"},{"key":"13831_CR50","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1016\/j.neuro.2016.03.020","volume":"61","author":"KA McKay","year":"2017","unstructured":"McKay KA, Jahanfar S, Duggan T, Tkachuk S, Tremlett H (2017) Factors associated with onset, relapses or progression in multiple sclerosis: a systematic review. Neurotoxicology 61:189\u2013212. https:\/\/doi.org\/10.1016\/j.neuro.2016.03.020","journal-title":"Neurotoxicology"},{"issue":"9","key":"13831_CR51","doi-asserted-by":"publisher","first-page":"805","DOI":"10.1016\/S1474-4422(07)70216-8","volume":"6","author":"DM Wingerchuk","year":"2007","unstructured":"Wingerchuk DM, Lennon VA, Lucchinetti CF, Pittock SJ, Weinshenker BG (2007) The spectrum of neuromyelitis optica. Lancet Neurol 6(9):805\u2013815. https:\/\/doi.org\/10.1016\/S1474-4422(07)70216-8","journal-title":"Lancet Neurol"},{"key":"13831_CR52","doi-asserted-by":"publisher","first-page":"1073278","DOI":"10.3389\/fpubh.2023.1073278","volume":"11","author":"Z Qian","year":"2023","unstructured":"Qian Z, Li Y, Guan Z, Guo P, Zheng K, Du Y et al (2023) Global, regional, and national burden of multiple sclerosis from 1990 to 2019: findings of the Global Burden of Disease Study 2019. Front Public Health 11:1073278. https:\/\/doi.org\/10.3389\/fpubh.2023.1073278","journal-title":"Front Public Health"},{"issue":"11","key":"13831_CR53","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1038\/s41582-021-00556-y","volume":"17","author":"N Koch-Henriksen","year":"2021","unstructured":"Koch-Henriksen N, Magyari M (2021) Apparent changes in the epidemiology and severity of multiple sclerosis. Nat Rev Neurol 17(11):676\u2013688. https:\/\/doi.org\/10.1038\/s41582-021-00556-y","journal-title":"Nat Rev Neurol"},{"key":"13831_CR54","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2022.103932","volume":"63","author":"J Lane","year":"2022","unstructured":"Lane J, Ng HS, Poyser C, Lucas RM, Tremlett H (2022) Multiple sclerosis incidence: a systematic review of change over time by geographical region. Mult Scler Relat Disord 63:103932. https:\/\/doi.org\/10.1016\/j.msard.2022.103932","journal-title":"Mult Scler Relat Disord"},{"issue":"2","key":"13831_CR55","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-024-12861-9","volume":"272","author":"L Cacciaguerra","year":"2025","unstructured":"Cacciaguerra L, Sechi E, Komla-Soukha I, Chen JJ, Smith CY, Jenkins SM et al (2025) MOG antibody-associated disease epidemiology in Olmsted County, USA, and Martinique. J Neurol 272(2):118. https:\/\/doi.org\/10.1007\/s00415-024-12861-9","journal-title":"J Neurol"},{"key":"13831_CR56","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/j.jaut.2015.06.010","volume":"64","author":"JA Hollenbach","year":"2015","unstructured":"Hollenbach JA, Oksenberg JR (2015) The immunogenetics of multiple sclerosis: a comprehensive review. J Autoimmun 64:13\u201325. https:\/\/doi.org\/10.1016\/j.jaut.2015.06.010","journal-title":"J Autoimmun"},{"issue":"6460","key":"13831_CR57","doi-asserted-by":"publisher","DOI":"10.1126\/science.aav7188","volume":"365","author":"International Multiple Sclerosis Genetics Consortium","year":"2019","unstructured":"International Multiple Sclerosis Genetics Consortium, ANZgene, IIBDGC, WTCCC2 (2019) Multiple sclerosis genomic map implicates peripheral immune cells and microglia in susceptibility. Science 365(6460):eaav7188. https:\/\/doi.org\/10.1126\/science.aav7188","journal-title":"Science"},{"issue":"1","key":"13831_CR58","doi-asserted-by":"publisher","first-page":"13706","DOI":"10.1038\/s41598-020-70699-2","volume":"10","author":"S Romero-Hidalgo","year":"2020","unstructured":"Romero-Hidalgo S, Flores-Rivera J, Rivas-Alonso V, Barquera R, Villarreal-Molina MT, Antuna-Puente B et al (2020) Native American ancestry significantly contributes to neuromyelitis optica susceptibility in the admixed Mexican population. Sci Rep 10(1):13706. https:\/\/doi.org\/10.1038\/s41598-020-70699-2","journal-title":"Sci Rep"},{"issue":"11","key":"13831_CR59","doi-asserted-by":"publisher","first-page":"2082","DOI":"10.1002\/acn3.51213","volume":"7","author":"T Matsushita","year":"2020","unstructured":"Matsushita T, Masaki K, Isobe N, Sato S, Yamamoto K, Nakamura Y et al (2020) Genetic factors for susceptibility to and manifestations of neuromyelitis optica. Ann Clin Transl Neurol 7(11):2082\u20132093. https:\/\/doi.org\/10.1002\/acn3.51213","journal-title":"Ann Clin Transl Neurol"},{"issue":"7","key":"13831_CR60","doi-asserted-by":"publisher","first-page":"2294","DOI":"10.1111\/ene.14848","volume":"28","author":"X Zhong","year":"2021","unstructured":"Zhong X, Chen C, Sun X, Wang J, Li R, Chang Y et al (2021) Whole-exome sequencing reveals the major genetic factors contributing to neuromyelitis optica spectrum disorder in Chinese patients with aquaporin 4-IgG seropositivity. Eur J Neurol 28(7):2294\u20132304. https:\/\/doi.org\/10.1111\/ene.14848","journal-title":"Eur J Neurol"},{"issue":"7","key":"13831_CR61","doi-asserted-by":"publisher","first-page":"1502","DOI":"10.1002\/acn3.51394","volume":"8","author":"M Grant-Peters","year":"2021","unstructured":"Grant-Peters M, Passos GRD, Yeung HY, Jacob A, Huda S, Leite MI et al (2021) No strong HLA association with MOG antibody disease in the UK population. Ann Clin Transl Neurol 8(7):1502\u20131507. https:\/\/doi.org\/10.1002\/acn3.51394","journal-title":"Ann Clin Transl Neurol"},{"issue":"7","key":"13831_CR62","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1136\/jnnp-2019-322548","volume":"91","author":"X Sun","year":"2020","unstructured":"Sun X, Qiu W, Wang J, Wang S, Wang Y, Zhong X et al (2020) Myelin oligodendrocyte glycoprotein-associated disorders are associated with HLA subtypes in a Chinese paediatric-onset cohort. J Neurol Neurosurg Psychiatry 91(7):733\u2013739. https:\/\/doi.org\/10.1136\/jnnp-2019-322548","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"9","key":"13831_CR63","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1038\/nri3871","volume":"15","author":"CA Dendrou","year":"2015","unstructured":"Dendrou CA, Fugger L, Friese MA (2015) Immunopathology of multiple sclerosis. Nat Rev Immunol 15(9):545\u2013558. https:\/\/doi.org\/10.1038\/nri3871","journal-title":"Nat Rev Immunol"},{"issue":"7969","key":"13831_CR64","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1038\/s41586-023-06250-x","volume":"619","author":"International Multiple Sclerosis Genetics Consortium","year":"2023","unstructured":"International Multiple Sclerosis Genetics Consortium, MultipleMS Consortium (2023) Locus for severity implicates CNS resilience in progression of multiple sclerosis. Nature 619(7969):323\u2013331. https:\/\/doi.org\/10.1038\/s41586-023-06250-x","journal-title":"Nature"},{"issue":"10","key":"13831_CR65","doi-asserted-by":"publisher","first-page":"772","DOI":"10.1038\/nri1707","volume":"5","author":"KA Hogquist","year":"2005","unstructured":"Hogquist KA, Baldwin TA, Jameson SC (2005) Central tolerance: learning self-control in the thymus. Nat Rev Immunol 5(10):772\u2013782. https:\/\/doi.org\/10.1038\/nri1707","journal-title":"Nat Rev Immunol"},{"issue":"1","key":"13831_CR66","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1111\/j.1600-065X.2011.01016.x","volume":"241","author":"JM Goverman","year":"2011","unstructured":"Goverman JM (2011) Immune tolerance in multiple sclerosis. Immunol Rev 241(1):228\u2013240. https:\/\/doi.org\/10.1111\/j.1600-065X.2011.01016.x","journal-title":"Immunol Rev"},{"issue":"7994","key":"13831_CR67","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1038\/s41586-023-06618-z","volume":"625","author":"W Barrie","year":"2024","unstructured":"Barrie W, Yang Y, Irving-Pease EK, Attfield KE, Scorrano G, Jensen LT et al (2024) Elevated genetic risk for multiple sclerosis emerged in steppe pastoralist populations. Nature 625(7994):321\u2013328. https:\/\/doi.org\/10.1038\/s41586-023-06618-z","journal-title":"Nature"},{"issue":"3","key":"13831_CR68","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1038\/gene.2016.5","volume":"17","author":"JA Hollenbach","year":"2016","unstructured":"Hollenbach JA, Pando MJ, Caillier SJ, Gourraud P-A, Oksenberg JR (2016) The killer immunoglobulin-like receptor KIR3DL1 in combination with HLA-Bw4 is protective against multiple sclerosis in African Americans. Genes Immun 17(3):199\u2013202. https:\/\/doi.org\/10.1038\/gene.2016.5","journal-title":"Genes Immun"},{"issue":"3","key":"13831_CR69","doi-asserted-by":"publisher","DOI":"10.1212\/NXI.0000000000000702","volume":"7","author":"AL Bruijstens","year":"2020","unstructured":"Bruijstens AL, Wong YYM, van Pelt DE, van der Linden PJ, Haasnoot GW, Hintzen RQ et al (2020) HLA association in MOG-IgG- and AQP4-IgG-related disorders of the CNS in the Dutch population. Neurol Neuroimmunol Neuroinflamm 7(3):e702. https:\/\/doi.org\/10.1212\/NXI.0000000000000702","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"issue":"6","key":"13831_CR70","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1177\/1352458513505693","volume":"20","author":"A Lossius","year":"2014","unstructured":"Lossius A, Riise T, Pugliatti M, Bj\u00f8rnevik K, Casetta I, Drulovic J et al (2014) Season of infectious mononucleosis and risk of multiple sclerosis at different latitudes; the EnvIMS Study. Mult Scler J 20(6):669\u2013674. https:\/\/doi.org\/10.1177\/1352458513505693","journal-title":"Mult Scler J"},{"issue":"14","key":"13831_CR71","doi-asserted-by":"publisher","first-page":"1856","DOI":"10.1177\/1352458515578770","volume":"21","author":"M Cortese","year":"2015","unstructured":"Cortese M, Riise T, Bj\u00f8rnevik K, Holm\u00f8y T, Kampman MT, Magalhaes S et al (2015) Timing of use of cod liver oil, a vitamin D source, and multiple sclerosis risk: the EnvIMS study. Mult Scler J 21(14):1856\u20131864. https:\/\/doi.org\/10.1177\/1352458515578770","journal-title":"Mult Scler J"},{"issue":"7","key":"13831_CR72","doi-asserted-by":"publisher","first-page":"1018","DOI":"10.1177\/1352458516671028","volume":"23","author":"K Bj\u00f8rnevik","year":"2017","unstructured":"Bj\u00f8rnevik K, Riise T, Bostrom I, Casetta I, Cortese M, Granieri E et al (2017) Negative interaction between smoking and EBV in the risk of multiple sclerosis: the EnvIMS study. Mult Scler J 23(7):1018\u20131024. https:\/\/doi.org\/10.1177\/1352458516671028","journal-title":"Mult Scler J"},{"issue":"8","key":"13831_CR73","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1001866","volume":"12","author":"LE Mokry","year":"2015","unstructured":"Mokry LE, Ross S, Ahmad OS, Forgetta V, Smith GD, Leong A et al (2015) Vitamin D and risk of multiple sclerosis: a Mendelian randomization study. PLoS Med 12(8):e1001866. https:\/\/doi.org\/10.1371\/journal.pmed.1001866","journal-title":"PLoS Med"},{"issue":"3","key":"13831_CR74","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1001\/jamaneurol.2013.5993","volume":"71","author":"A Ascherio","year":"2014","unstructured":"Ascherio A, Munger KL, White R, K\u00f6chert K, Simon KC, Polman CH et al (2014) Vitamin D as an early predictor of multiple sclerosis activity and progression. JAMA Neurol 71(3):306\u2013314. https:\/\/doi.org\/10.1001\/jamaneurol.2013.5993","journal-title":"JAMA Neurol"},{"issue":"11","key":"13831_CR75","doi-asserted-by":"publisher","first-page":"1193","DOI":"10.1136\/jnnp-2018-320189","volume":"90","author":"S Simpson","year":"2019","unstructured":"Simpson S, Wang W, Otahal P, Blizzard L, van der Mei IA, Taylor BV (2019) Latitude continues to be significantly associated with the prevalence of multiple sclerosis: an updated meta-analysis. J Neurol Neurosurg Psychiatry 90(11):1193\u20131200. https:\/\/doi.org\/10.1136\/jnnp-2018-320189","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"4","key":"13831_CR76","doi-asserted-by":"publisher","first-page":"742","DOI":"10.1016\/j.neuron.2018.01.021","volume":"97","author":"C Baecher-Allan","year":"2018","unstructured":"Baecher-Allan C, Kaskow BJ, Weiner HL (2018) Multiple sclerosis: mechanisms and immunotherapy. Neuron 97(4):742\u2013768. https:\/\/doi.org\/10.1016\/j.neuron.2018.01.021","journal-title":"Neuron"},{"issue":"4","key":"13831_CR77","doi-asserted-by":"publisher","DOI":"10.3390\/biom12040538","volume":"12","author":"TG Schreiner","year":"2022","unstructured":"Schreiner TG, Romanescu C, Popescu BO (2022) The blood-brain barrier\u2014a key player in multiple sclerosis disease mechanisms. Biomolecules 12(4):538. https:\/\/doi.org\/10.3390\/biom12040538","journal-title":"Biomolecules"},{"issue":"7","key":"13831_CR78","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1016\/j.nrleng.2021.10.005","volume":"37","author":"L Mart\u00edn-Aguilar","year":"2022","unstructured":"Mart\u00edn-Aguilar L, Presas-Rodriguez S, Rovira \u00c0, Capellades J, Massuet-Vilamaj\u00f3 A, Rami\u00f3-Torrent\u00e0 L et al (2022) Gadolinium-enhanced brain lesions in multiple sclerosis relapse. Neurolog\u00eda (English Edition) 37(7):557\u2013563. https:\/\/doi.org\/10.1016\/j.nrleng.2021.10.005","journal-title":"Neurolog\u00eda (English Edition)"},{"issue":"16","key":"13831_CR79","doi-asserted-by":"publisher","DOI":"10.3390\/ijms22168370","volume":"22","author":"R Balasa","year":"2021","unstructured":"Balasa R, Barcutean L, Mosora O, Manu D (2021) Reviewing the significance of blood-brain barrier disruption in multiple sclerosis pathology and treatment. Int J Mol Sci 22(16):8370. https:\/\/doi.org\/10.3390\/ijms22168370","journal-title":"Int J Mol Sci"},{"issue":"7","key":"13831_CR80","doi-asserted-by":"publisher","DOI":"10.1002\/cti2.1316","volume":"10","author":"JA Lopez","year":"2021","unstructured":"Lopez JA, Denkova M, Ramanathan S, Dale RC, Brilot F (2021) Pathogenesis of autoimmune demyelination: from multiple sclerosis to neuromyelitis optica spectrum disorders and myelin oligodendrocyte glycoprotein antibody-associated disease. Clin Transl Immunol 10(7):e1316. https:\/\/doi.org\/10.1002\/cti2.1316","journal-title":"Clin Transl Immunol"},{"issue":"6","key":"13831_CR81","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1002\/1531-8249(200006)47:6<707::AID-ANA3>3.0.CO;2-Q","volume":"47","author":"C Lucchinetti","year":"2000","unstructured":"Lucchinetti C, Br\u00fcck W, Parisi J, Scheithauer B, Rodriguez M, Lassmann H (2000) Heterogeneity of multiple sclerosis lesions: implications for the pathogenesis of demyelination. Ann Neurol 47(6):707\u2013717. https:\/\/doi.org\/10.1002\/1531-8249(200006)47:6%3c707::AID-ANA3%3e3.0.CO;2-Q","journal-title":"Ann Neurol"},{"issue":"5","key":"13831_CR82","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1056\/NEJM199801293380502","volume":"338","author":"BD Trapp","year":"1998","unstructured":"Trapp BD, Peterson J, Ransohoff RM, Rudick R, M\u00f6rk S, B\u00f6 L (1998) Axonal transection in the lesions of multiple sclerosis. N Engl J Med 338(5):278\u2013285. https:\/\/doi.org\/10.1056\/NEJM199801293380502","journal-title":"N Engl J Med"},{"issue":"1","key":"13831_CR83","doi-asserted-by":"publisher","DOI":"10.1186\/s12974-021-02249-1","volume":"18","author":"E Carnero Contentti","year":"2021","unstructured":"Carnero Contentti E, Correale J (2021) Neuromyelitis optica spectrum disorders: from pathophysiology to therapeutic strategies. J Neuroinflammation 18(1):208. https:\/\/doi.org\/10.1186\/s12974-021-02249-1","journal-title":"J Neuroinflammation"},{"key":"13831_CR84","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2023.1137998","volume":"14","author":"O Corbali","year":"2023","unstructured":"Corbali O, Chitnis T (2023) Pathophysiology of myelin oligodendrocyte glycoprotein antibody disease. Front Neurol 14:1137998. https:\/\/doi.org\/10.3389\/fneur.2023.1137998","journal-title":"Front Neurol"},{"issue":"9","key":"13831_CR85","doi-asserted-by":"publisher","first-page":"762","DOI":"10.1016\/S1474-4422(21)00218-0","volume":"20","author":"R Marignier","year":"2021","unstructured":"Marignier R, Hacohen Y, Cobo-Calvo A, Pr\u00f6bstel A-K, Aktas O, Alexopoulos H et al (2021) Myelin-oligodendrocyte glycoprotein antibody-associated disease. Lancet Neurol 20(9):762\u2013772. https:\/\/doi.org\/10.1016\/S1474-4422(21)00218-0","journal-title":"Lancet Neurol"},{"issue":"5","key":"13831_CR86","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1007\/s00401-020-02132-y","volume":"139","author":"R H\u00f6ftberger","year":"2020","unstructured":"H\u00f6ftberger R, Guo Y, Flanagan EP, Lopez-Chiriboga AS, Endmayr V, Hochmeister S et al (2020) The pathology of central nervous system inflammatory demyelinating disease accompanying myelin oligodendrocyte glycoprotein autoantibody. Acta Neuropathol 139(5):875\u2013892. https:\/\/doi.org\/10.1007\/s00401-020-02132-y","journal-title":"Acta Neuropathol"},{"issue":"17","key":"13831_CR87","doi-asserted-by":"publisher","DOI":"10.3390\/ijms26178538","volume":"26","author":"T Misu","year":"2025","unstructured":"Misu T (2025) Myelin oligodendrocyte glycoprotein antibody-associated disease: pathophysiology, clinical patterns, and therapeutic challenges of intractable and severe forms. Int J Mol Sci 26(17):8538. https:\/\/doi.org\/10.3390\/ijms26178538","journal-title":"Int J Mol Sci"},{"issue":"3","key":"13831_CR88","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1136\/practneurol-2018-002074","volume":"19","author":"M Jury\u0144czyk","year":"2019","unstructured":"Jury\u0144czyk M, Jacob A, Fujihara K, Palace J (2019) Myelin oligodendrocyte glycoprotein (MOG) antibody-associated disease: practical considerations. Pract Neurol 19(3):187\u2013195. https:\/\/doi.org\/10.1136\/practneurol-2018-002074","journal-title":"Pract Neurol"},{"key":"13831_CR89","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.933415","volume":"13","author":"P Nytrova","year":"2022","unstructured":"Nytrova P, Dolezal O (2022) Sex bias in multiple sclerosis and neuromyelitis optica spectrum disorders: how it influences clinical course, MRI parameters and prognosis. Front Immunol 13:933415. https:\/\/doi.org\/10.3389\/fimmu.2022.933415","journal-title":"Front Immunol"},{"issue":"5","key":"13831_CR90","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1038\/nrneurol.2012.43","volume":"8","author":"RR Voskuhl","year":"2012","unstructured":"Voskuhl RR, Gold SM (2012) Sex-related factors in multiple sclerosis susceptibility and progression. Nat Rev Neurol 8(5):255\u2013263. https:\/\/doi.org\/10.1038\/nrneurol.2012.43","journal-title":"Nat Rev Neurol"},{"issue":"2","key":"13831_CR91","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1007\/s00296-023-05446-8","volume":"44","author":"LI Sakkas","year":"2024","unstructured":"Sakkas LI, Chikanza IC (2024) Sex bias in immune response: it is time to include the sex variable in studies of autoimmune rheumatic diseases. Rheumatol Int 44(2):203\u2013209. https:\/\/doi.org\/10.1007\/s00296-023-05446-8","journal-title":"Rheumatol Int"},{"key":"13831_CR92","doi-asserted-by":"publisher","DOI":"10.1016\/j.nbd.2023.106113","volume":"181","author":"JF Catal\u00e0-Senent","year":"2023","unstructured":"Catal\u00e0-Senent JF, Andreu Z, Hidalgo MR, Soler-S\u00e1ez I, Roig FJ, Yanguas-Cas\u00e1s N et al (2023) A deep transcriptome meta-analysis reveals sex differences in multiple sclerosis. Neurobiol Dis 181:106113. https:\/\/doi.org\/10.1016\/j.nbd.2023.106113","journal-title":"Neurobiol Dis"},{"key":"13831_CR93","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1175874","volume":"14","author":"N Alvarez-Sanchez","year":"2023","unstructured":"Alvarez-Sanchez N, Dunn SE (2023) Potential biological contributers to the sex difference in multiple sclerosis progression. Front Immunol 14:1175874. https:\/\/doi.org\/10.3389\/fimmu.2023.1175874","journal-title":"Front Immunol"},{"issue":"1","key":"13831_CR94","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1111\/imm.13004","volume":"156","author":"MC Ysrraelit","year":"2019","unstructured":"Ysrraelit MC, Correale J (2019) Impact of sex hormones on immune function and multiple sclerosis development. Immunology 156(1):9\u201322. https:\/\/doi.org\/10.1111\/imm.13004","journal-title":"Immunology"},{"issue":"9","key":"13831_CR95","doi-asserted-by":"publisher","first-page":"4471","DOI":"10.1007\/s10072-024-07501-z","volume":"45","author":"Y Hu","year":"2024","unstructured":"Hu Y, Zou F, Lu W (2024) Sex hormones and neuromyelitis optica spectrum disorder: a bidirectional Mendelian randomization study. Neurol Sci 45(9):4471\u20134479. https:\/\/doi.org\/10.1007\/s10072-024-07501-z","journal-title":"Neurol Sci"},{"issue":"7","key":"13831_CR96","doi-asserted-by":"publisher","DOI":"10.3390\/brainsci12070885","volume":"12","author":"AK Szewczyk","year":"2022","unstructured":"Szewczyk AK, Papu\u0107 E, Mitosek-Szewczyk K, Wo\u015b M, Rejdak K (2022) NMOSD\u2014diagnostic dilemmas leading towards final diagnosis. Brain Sci 12(7):885. https:\/\/doi.org\/10.3390\/brainsci12070885","journal-title":"Brain Sci"},{"key":"13831_CR97","doi-asserted-by":"publisher","DOI":"10.1177\/1756286420956495","volume":"13","author":"PS Rommer","year":"2020","unstructured":"Rommer PS, Ellenberger D, Hellwig K, Haas J, P\u00f6hlau D, Stahmann A et al (2020) Relapsing and progressive MS: the sex-specific perspective. Ther Adv Neurol Disord 13:1756286420956495. https:\/\/doi.org\/10.1177\/1756286420956495","journal-title":"Ther Adv Neurol Disord"},{"key":"13831_CR98","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2021.554375","volume":"12","author":"R Bove","year":"2021","unstructured":"Bove R, Okai A, Houtchens M, Elias-Hamp B, Lugaresi A, Hellwig K et al (2021) Effects of menopause in women with multiple sclerosis: an evidence-based review. Front Neurol 12:554375. https:\/\/doi.org\/10.3389\/fneur.2021.554375","journal-title":"Front Neurol"},{"key":"13831_CR99","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/j.msard.2017.01.001","volume":"12","author":"R Li","year":"2017","unstructured":"Li R, Sun X, Shu Y, Mao Z, Xiao L, Qiu W et al (2017) Sex differences in outcomes of disease-modifying treatments for multiple sclerosis: a systematic review. Mult Scler Relat Disord 12:23\u201328. https:\/\/doi.org\/10.1016\/j.msard.2017.01.001","journal-title":"Mult Scler Relat Disord"},{"issue":"7","key":"13831_CR100","doi-asserted-by":"publisher","DOI":"10.3390\/jcm10071441","volume":"10","author":"A Farkouh","year":"2021","unstructured":"Farkouh A, Baumg\u00e4rtel C, Gottardi R, Hemetsberger M, Czejka M, Kautzky-Willer A (2021) Sex-related differences in drugs with anti-inflammatory properties. J Clin Med 10(7):1441. https:\/\/doi.org\/10.3390\/jcm10071441","journal-title":"J Clin Med"},{"key":"13831_CR101","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1016\/j.yfrne.2018.07.001","volume":"50","author":"MK Houtchens","year":"2018","unstructured":"Houtchens MK, Bove R (2018) A case for gender-based approach to multiple sclerosis therapeutics. Front Neuroendocrinol 50:123\u2013134. https:\/\/doi.org\/10.1016\/j.yfrne.2018.07.001","journal-title":"Front Neuroendocrinol"},{"key":"13831_CR102","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.800666","volume":"12","author":"S Deng","year":"2022","unstructured":"Deng S, Lei Q, Lu W (2022) Pregnancy-related attack in neuromyelitis optica spectrum disorder with AQP4-IgG: a single-center study and meta-analysis. Front Immunol 12:800666. https:\/\/doi.org\/10.3389\/fimmu.2021.800666","journal-title":"Front Immunol"},{"issue":"5","key":"13831_CR103","doi-asserted-by":"publisher","first-page":"1499","DOI":"10.1182\/blood-2010-07-295444","volume":"117","author":"EF Chakravarty","year":"2011","unstructured":"Chakravarty EF, Murray ER, Kelman A, Farmer P (2011) Pregnancy outcomes after maternal exposure to rituximab. Blood 117(5):1499\u20131506. https:\/\/doi.org\/10.1182\/blood-2010-07-295444","journal-title":"Blood"},{"key":"13831_CR104","unstructured":"Amgen Inc. UPLIZNA (inebilizumab-cdon) injection, for intravenous use: prescribing information. Thousand Oaks (CA): Amgen Inc.; 2025. Available from: US Food and Drug Administration."},{"issue":"5","key":"13831_CR105","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1093\/humupd\/dmp004","volume":"15","author":"LR Guerin","year":"2009","unstructured":"Guerin LR, Prins JR, Robertson SA (2009) Regulatory T-cells and immune tolerance in pregnancy: a new target for infertility treatment? Hum Reprod Update 15(5):517\u2013535. https:\/\/doi.org\/10.1093\/humupd\/dmp004","journal-title":"Hum Reprod Update"},{"issue":"6","key":"13831_CR106","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1007\/s00281-016-0584-y","volume":"38","author":"SM Gold","year":"2016","unstructured":"Gold SM, Voskuhl RR (2016) Pregnancy and multiple sclerosis: from molecular mechanisms to clinical application. Semin Immunopathol 38(6):631\u2013763","journal-title":"Semin Immunopathol"},{"issue":"6","key":"13831_CR107","doi-asserted-by":"publisher","first-page":"1157","DOI":"10.1097\/AOG.0000000000000541","volume":"124","author":"R Bove","year":"2014","unstructured":"Bove R, Alwan S, Friedman JM, Hellwig K, Houtchens M, Koren G et al (2014) Management of multiple sclerosis during pregnancy and the reproductive years: a systematic review. Obstet Gynecol 124(6):1157\u20131168. https:\/\/doi.org\/10.1097\/AOG.0000000000000541","journal-title":"Obstet Gynecol"},{"issue":"10","key":"13831_CR108","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1055\/s-0044-1791202","volume":"82","author":"EMV Melo","year":"2024","unstructured":"Melo EMV, Rodrigues BCA, Cabral FT, Villarim LAMT, Mendes MF (2024) Patient-centered pregnancy planning in multiple sclerosis: evidence for a new era. Arq Neuropsiquiatr 82(10):1\u201311. https:\/\/doi.org\/10.1055\/s-0044-1791202","journal-title":"Arq Neuropsiquiatr"},{"issue":"4","key":"13831_CR109","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1016\/S1474-4422(22)00426-4","volume":"22","author":"KM Krysko","year":"2023","unstructured":"Krysko KM, Dobson R, Alroughani R, Amato MP, Bove R, Ciplea AI, Fragoso Y, Houtchens M, Jokubaitis VG, Magyari M, Abdelnasser A, Padma V, Thiel S, Tintore M, Vukusic S, Hellwig K (2023) Family planning considerations in people with multiple sclerosis. Lancet Neurol 22(4):350\u2013366. https:\/\/doi.org\/10.1016\/S1474-4422(22)00426-4","journal-title":"Lancet Neurol"},{"key":"13831_CR110","unstructured":"Novartis Pharmaceuticals Corporation. GILENYA (fingolimod) capsules: prescribing information. East Hanover (NJ): Novartis Pharmaceuticals Corporation. Available from: US Food and Drug Administration"},{"key":"13831_CR111","unstructured":"Novartis Pharmaceuticals Corporation. MAYZENT (siponimod) tablets, for oral use: prescribing information. East Hanover (NJ): Novartis Pharmaceuticals Corporation; 2024. Available from: US Food and Drug Administration"},{"key":"13831_CR112","unstructured":"Bristol-Myers Squibb Company. ZEPOSIA (ozanimod) capsules, for oral use: prescribing information. Princeton (NJ): Bristol-Myers Squibb Company; 2024. Available from: US Food and Drug Administration"},{"key":"13831_CR113","unstructured":"Janssen Pharmaceuticals, Inc. PONVORY (ponesimod) tablets, for oral use: prescribing information. Titusville (NJ): Janssen Pharmaceuticals, Inc.; 2021. Available from: US Food and Drug Administration"},{"key":"13831_CR114","unstructured":"Genzyme Corporation. AUBAGIO (teriflunomide) tablets, for oral use: prescribing information. Cambridge (MA): Genzyme Corporation; 2024. Available from: US Food and Drug Administration"},{"issue":"2","key":"13831_CR115","doi-asserted-by":"publisher","DOI":"10.3390\/medicina56020049","volume":"56","author":"G Varyt\u0117","year":"2020","unstructured":"Varyt\u0117 G, Zakarevi\u010dien\u0117 J, Rama\u0161auskait\u0117 D, Lau\u017eikien\u0117 D, Arlauskien\u0117 A (2020) Pregnancy and multiple sclerosis: an update on the disease modifying treatment strategy and a review of pregnancy\u2019s impact on disease activity. Medicina (Kaunas) 56(2):49. https:\/\/doi.org\/10.3390\/medicina56020049","journal-title":"Medicina (Kaunas)"},{"key":"13831_CR116","unstructured":"EMD Serono, Inc. MAVENCLAD (cladribine) tablets: prescribing information. Rockland (MA): EMD Serono, Inc.; 2024. Available from: US Food and Drug Administration."},{"key":"13831_CR117","unstructured":"Genentech, Inc. OCREVUS (ocrelizumab) injection, for intravenous use: prescribing information. South San Francisco (CA): Genentech, Inc.; 2022. Available from: US Food and Drug Administration."},{"key":"13831_CR118","unstructured":"Novartis Pharmaceuticals Corporation. KESIMPTA (ofatumumab) injection, for subcutaneous use: prescribing information. East Hanover (NJ): Novartis Pharmaceuticals Corporation; 2024. Available from: US Food and Drug Administration."},{"issue":"12","key":"13831_CR119","doi-asserted-by":"publisher","first-page":"4522","DOI":"10.1007\/s00415-020-10235-5","volume":"268","author":"T Holm\u00f8y","year":"2021","unstructured":"Holm\u00f8y T, H\u00f8glund RA, Illes Z, Myhr KM, Torkildsen \u00d8 (2021) Recent progress in maintenance treatment of neuromyelitis optica spectrum disorder. J Neurol 268(12):4522\u20134536","journal-title":"J Neurol"},{"issue":"1","key":"13831_CR120","doi-asserted-by":"publisher","first-page":"2","DOI":"10.4103\/sjopt.sjopt_102_23","volume":"38","author":"N Tisavipat","year":"2024","unstructured":"Tisavipat N, Juan HY, Chen JJ (2024) Monoclonal antibody therapies for aquaporin-4-immunoglobulin G-positive neuromyelitis optica spectrum disorder and myelin oligodendrocyte glycoprotein antibody-associated disease. Saudi J Ophthalmol 38(1):2\u201312","journal-title":"Saudi J Ophthalmol"},{"key":"13831_CR121","doi-asserted-by":"publisher","DOI":"10.1177\/17562864251384504","volume":"18","author":"Y Shimizu","year":"2025","unstructured":"Shimizu Y, Ikeguchi R, Fujihara K, Todo K (2025) Progress in the management of pregnancy in patients with neuromyelitis optica spectrum disorder. Ther Adv Neurol Disord 18:17562864251384504. https:\/\/doi.org\/10.1177\/17562864251384504","journal-title":"Ther Adv Neurol Disord"},{"key":"13831_CR122","unstructured":"Biogen Inc. TYSABRI (natalizumab) injection, for intravenous use: prescribing information. Cambridge (MA): Biogen Inc.; 2025. Available from: US Food and Drug Administration."},{"key":"13831_CR123","unstructured":"Biogen MA Inc. AVONEX (interferon beta-1a) injection, for intramuscular use: prescribing information. Cambridge (MA): Biogen MA Inc.; 2021. Available from: US Food and Drug Administration."},{"key":"13831_CR124","unstructured":"Teva Pharmaceuticals USA, Inc. COPAXONE (glatiramer acetate injection), for subcutaneous use: prescribing information. Parsippany (NJ): Teva Pharmaceuticals USA, Inc.; 2025. Available from: US Food and Drug Administration."},{"key":"13831_CR125","unstructured":"Genzyme Corporation. LEMTRADA (alemtuzumab) injection, for intravenous use. Cambridge (MA): Genzyme Corporation; 2024. Available from: US Food and Drug Administration."},{"issue":"6","key":"13831_CR126","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1136\/jnnp-2023-332804","volume":"95","author":"S Thiel","year":"2024","unstructured":"Thiel S, Litvin N, Haben S, Gold R, Hellwig K (2024) Disease activity and neonatal outcomes after exposure to natalizumab throughout pregnancy. J Neurol Neurosurg Psychiatry 95(6):561\u2013570. https:\/\/doi.org\/10.1136\/jnnp-2023-332804","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"4","key":"13831_CR127","doi-asserted-by":"publisher","DOI":"10.1212\/NXG.0000000000000088","volume":"2","author":"R Bove","year":"2016","unstructured":"Bove R, Chua AS, Xia Z, Chibnik L, De Jager PL, Chitnis T (2016) Complex relation of HLA-DRB1*1501, age at menarche, and age at multiple sclerosis onset. Neurol Genet 2(4):e88. https:\/\/doi.org\/10.1212\/NXG.0000000000000088","journal-title":"Neurol Genet"},{"issue":"3","key":"13831_CR128","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1191\/135248506ms1267oa","volume":"12","author":"J Sloka","year":"2006","unstructured":"Sloka J, Pryse-Phillips WE, Stefanelli M (2006) The relation between menarche and the age of first symptoms in a multiple sclerosis cohort. Mult Scler J 12(3):333\u2013339. https:\/\/doi.org\/10.1191\/135248506ms1267oa","journal-title":"Mult Scler J"},{"issue":"7","key":"13831_CR129","doi-asserted-by":"publisher","DOI":"10.3390\/ijms24076354","volume":"24","author":"A Bianco","year":"2023","unstructured":"Bianco A, Antonacci Y, Liguori M (2023) Sex and gender differences in neurodegenerative diseases: challenges for therapeutic opportunities. Int J Mol Sci 24(7):6354. https:\/\/doi.org\/10.3390\/ijms24076354","journal-title":"Int J Mol Sci"},{"issue":"10","key":"13831_CR130","doi-asserted-by":"publisher","first-page":"1006","DOI":"10.3390\/jpm11101006","volume":"11","author":"PK Coyle","year":"2021","unstructured":"Coyle PK (2021) What can we learn from sex differences in MS? J Pers Med 11(10):1006. https:\/\/doi.org\/10.3390\/jpm11101006","journal-title":"J Pers Med"},{"key":"13831_CR131","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/j.msard.2018.07.006","volume":"25","author":"Y Tong","year":"2018","unstructured":"Tong Y, Liu J, Yang T, Kang Y, Wang J, Zhao T et al (2018) Influences of pregnancy on neuromyelitis optica spectrum disorders and multiple sclerosis. Multiple Sclerosis and Related Disorders 25:61\u201365. https:\/\/doi.org\/10.1016\/j.msard.2018.07.006","journal-title":"Multiple Sclerosis and Related Disorders"},{"issue":"1","key":"13831_CR132","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1002\/ana.25909","volume":"89","author":"A Cobo-Calvo","year":"2021","unstructured":"Cobo-Calvo A, Ruiz A, Rollot F, Arrambide G, Deschamps R, Maillart E et al (2021) Clinical features and risk of relapse in children and adults with myelin oligodendrocyte glycoprotein antibody-associated disease. Ann Neurol 89(1):30\u201341. https:\/\/doi.org\/10.1002\/ana.25909","journal-title":"Ann Neurol"},{"issue":"1","key":"13831_CR133","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1186\/s13048-024-01483-4","volume":"17","author":"A Arabipoor","year":"2024","unstructured":"Arabipoor A, Moini A, Nabavi SM, Mohiti S, Mashayekhi M, Zolfaghari Z (2024) Evaluation of ovarian reserve and the assisted reproductive technology (ART) cycles\u2019 outcome as well as the relapse rate within one year after ART in women with multiple sclerosis: a case-control study. Journal of Ovarian Research 17(1):165. https:\/\/doi.org\/10.1186\/s13048-024-01483-4","journal-title":"Journal of Ovarian Research"},{"issue":"2","key":"13831_CR134","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1159\/000177937","volume":"61","author":"K Hellwig","year":"2009","unstructured":"Hellwig K, Schimrigk S, Beste C, M\u00fcller T, Gold R (2009) Increase in relapse rate during assisted reproduction technique in patients with multiple sclerosis. Eur Neurol 61(2):65\u201368. https:\/\/doi.org\/10.1159\/000177937","journal-title":"Eur Neurol"},{"key":"13831_CR135","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbih.2022.100484","volume":"24","author":"DS Peres","year":"2022","unstructured":"Peres DS, Rodrigues P, Viero FT, Frare JM, Kudsi SQ, Meira GM et al (2022) Prevalence of depression and anxiety in the different clinical forms of multiple sclerosis and associations with disability: a systematic review and meta-analysis. Brain Behav Immun Health 24:100484. https:\/\/doi.org\/10.1016\/j.bbih.2022.100484","journal-title":"Brain Behav Immun Health"},{"key":"13831_CR136","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2023.105084","volume":"77","author":"J Liu","year":"2023","unstructured":"Liu J, Chen Y, Zhang L, Ding M, Wang J, Wang H et al (2023) The prevalence of depression, anxiety, and sleep disturbances in neuromyelitis optica spectrum disorder: a systematic review and meta-analysis. Mult Scler Relat Disord 77:105084. https:\/\/doi.org\/10.1016\/j.msard.2023.105084","journal-title":"Mult Scler Relat Disord"},{"issue":"10","key":"13831_CR137","doi-asserted-by":"publisher","first-page":"1577","DOI":"10.1111\/ene.13052","volume":"23","author":"Z Shi","year":"2016","unstructured":"Shi Z, Chen H, Lian Z, Liu J, Feng H, Zhou H (2016) Factors that impact health-related quality of life in neuromyelitis optica spectrum disorder: anxiety, disability, fatigue and depression. Eur J Neurol 23(10):1577\u20131584. https:\/\/doi.org\/10.1111\/ene.13052","journal-title":"Eur J Neurol"},{"issue":"11","key":"13831_CR138","doi-asserted-by":"publisher","first-page":"662","DOI":"10.1038\/nrneurol.2017.117","volume":"13","author":"I-K Penner","year":"2017","unstructured":"Penner I-K, Paul F (2017) Fatigue as a symptom or comorbidity of neurological diseases. Nat Rev Neurol 13(11):662\u2013675. https:\/\/doi.org\/10.1038\/nrneurol.2017.117","journal-title":"Nat Rev Neurol"},{"issue":"1","key":"13831_CR139","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-025-13582-3","volume":"273","author":"R Rust","year":"2026","unstructured":"Rust R, Asseyer S, Schindler P, Chien C, Rekers S, Finke C et al (2026) Cognitive function in patients with myelin oligodendrocyte glycoprotein antibody-associated disease. J Neurol 273(1):61. https:\/\/doi.org\/10.1007\/s00415-025-13582-3","journal-title":"J Neurol"},{"issue":"8","key":"13831_CR140","doi-asserted-by":"publisher","first-page":"1123","DOI":"10.1177\/1352458517708687","volume":"23","author":"A Thompson","year":"2017","unstructured":"Thompson A, Kobelt G, Berg J, Gannedahl M, Eriksson J (2017) New insights into the burden and costs of multiple sclerosis in Europe. Mult Scler J 23(8):1123\u20131136. https:\/\/doi.org\/10.1177\/1352458517708687","journal-title":"Mult Scler J"},{"issue":"23","key":"13831_CR141","doi-asserted-by":"publisher","first-page":"e2789","DOI":"10.1212\/WNL.0000000000012062","volume":"96","author":"K Eid","year":"2021","unstructured":"Eid K, Torkildsen \u00d8F, Aarseth J et al (2021) Perinatal depression and anxiety in women with multiple sclerosis: a population-based cohort study. Neurology 96(23):e2789\u2013e2800. https:\/\/doi.org\/10.1212\/WNL.0000000000012062","journal-title":"Neurology"},{"key":"13831_CR142","doi-asserted-by":"publisher","DOI":"10.1016\/j.pec.2023.107673","volume":"110","author":"A Fragkoudi","year":"2023","unstructured":"Fragkoudi A, Rumbold AR, Grzeskowiak LE (2023) Family planning and multiple sclerosis: a qualitative study of patient experiences to understand information needs and promote informed decision-making. Patient Educ Couns 110:107673. https:\/\/doi.org\/10.1016\/j.pec.2023.107673","journal-title":"Patient Educ Couns"},{"issue":"9","key":"13831_CR143","doi-asserted-by":"publisher","DOI":"10.1002\/brb3.70839","volume":"15","author":"O Mirmosayyeb","year":"2025","unstructured":"Mirmosayyeb O, Khodadadi H, Zandifar A, Shaygannejad V, Eskandarieh S, Maghzi AH et al (2025) Suicide ideation, attempts, and mortality in multiple sclerosis: a systematic review and meta-analysis. Brain Behav 15(9):e70839. https:\/\/doi.org\/10.1002\/brb3.70839","journal-title":"Brain Behav"},{"issue":"8","key":"13831_CR144","doi-asserted-by":"publisher","first-page":"1329","DOI":"10.1111\/ene.13029","volume":"23","author":"P Brenner","year":"2016","unstructured":"Brenner P, Burman J, Jokinen J, Gottberg K, Landtblom AM, Nilsag\u00e5rd Y et al (2016) Multiple sclerosis and risk of attempted and completed suicide - a cohort study. Eur J Neurol 23(8):1329\u20131335. https:\/\/doi.org\/10.1111\/ene.13029","journal-title":"Eur J Neurol"},{"key":"13831_CR145","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1016\/j.msard.2015.10.004","volume":"5","author":"KM Fiest","year":"2016","unstructured":"Fiest KM, Walker JR, Bernstein CN, Graff LA, Zarychanski R, Abou-Setta AM et al (2016) Systematic review and meta-analysis of interventions for depression and anxiety in persons with multiple sclerosis. Mult Scler Relat Disord 5:12\u201326. https:\/\/doi.org\/10.1016\/j.msard.2015.10.004","journal-title":"Mult Scler Relat Disord"},{"key":"13831_CR146","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1016\/j.jpsychores.2016.09.002","volume":"90","author":"LE van den Akker","year":"2016","unstructured":"van den Akker LE, Beckerman H, Collette EH, Eijssen ICJM, Dekker J, de Groot V (2016) Effectiveness of cognitive behavioral therapy for the treatment of fatigue in patients with multiple sclerosis: A systematic review and meta-analysis. J Psychosom Res 90:33\u201342. https:\/\/doi.org\/10.1016\/j.jpsychores.2016.09.002","journal-title":"J Psychosom Res"}],"container-title":["Journal of Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00415-026-13831-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00415-026-13831-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00415-026-13831-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,22]],"date-time":"2026-05-22T10:44:04Z","timestamp":1779446644000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00415-026-13831-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,27]]},"references-count":146,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,5]]}},"alternative-id":["13831"],"URL":"https:\/\/doi.org\/10.1007\/s00415-026-13831-z","relation":{},"ISSN":["0340-5354","1432-1459"],"issn-type":[{"value":"0340-5354","type":"print"},{"value":"1432-1459","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,27]]},"assertion":[{"value":"16 February 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 April 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 April 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 April 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no conflicts of interest relevant to this article. All authors confirm that they have no financial or non-financial relationships, affiliations, or proprietary interests related to the subject matter discussed in this manuscript.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}},{"value":"The manuscript does not contain clinical studies or patient data.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}],"article-number":"290"}}